CG Oncology’s Post

Today we are proud to announce the initiation of our Expanded Access Program (EAP) for cretostimogene grenadenorepvec in the U.S. for patients with Non-Muscle Invasive Bladder Cancer (#NMIBC) who are unresponsive to Bacillus Calmette-Guerin (BCG) and meet certain program eligibility criteria. The first patient has been dosed in the EAP, and enrollment is ongoing. 📄 Read the full release here: https://bit.ly/3Rv5a7C Healthcare providers and bladder cancer patients who are interested to learn more about CG Oncology’s EAP including eligibility criteria may visit www.clinicaltrials.gov, NCT06443944, or contact EAP@cgoncology.com. #BladderCancer #ClinicalTrials #UroOncology #Immunotherapy #PatientCare #DrugDevelopment #Immunotherapy #Therapeutics #CGOncology #cretostimogene

Thank you to Targeted Oncology and Mark Tyson, M.D., M.P.H for sharing the encouraging results of the BOND-003 trial evaluating cretostimogene grenadenorepvec, CG Oncology's novel oncolytic immunotherapy candidate, in high-risk Bacillus Calmette-Guérin-Unresponsive Non-Muscle Invasive Bladder Cancer (#NMIBC). To read the article, please visit https://bit.ly/4d3aIi8 For more information on CG Oncology's ongoing clinical trials in bladder cancer, please visit https://bit.ly/4bKz1jL #BladderCancer #ClinicalTrials #UroOncology #Immunotherapy #PatientCare #DrugDevelopment #CGOncology #cretostimogene

CG Oncology is thrilled to welcome some new team members who will help us on our mission of Attacking Bladder Cancer for a Better Tomorrow™! Welcome to the team: Yordanis Diez, PharmD - Director, Product Marketing Kristen M. - Sr. Director, Marketing & Communications Estela Hwangbo - Senior Manager, Data Management Katja Birker, Ph.D. - Sr. Manager Commercial Insights & Analytics 

🩺 Navigating the complexities of Non-Muscle Invasive Bladder Cancer (#NMIBC) treatment options brings many uncertainties and challenges, particularly when it comes to recurrence. We sincerely thank the Bladder Cancer Advocacy Network (#BCAN) for raising awareness about CG Oncology's Expanded Access Program (EAP) for cretostimogene grenadenorepvec in the U.S. Learn more about our investigational, intravesically delivered oncolytic immunotherapy candidate for BCG-unresponsive NMIBC in this Urology Times article: https://bit.ly/3Ruv3Vq 🎗 Healthcare providers and bladder cancer patients can learn more about CG Oncology’s EAP and its eligibility criteria by visiting www.clinicaltrials.gov  (NCT06443944) or emailing EAP@cgoncology.com. #ClinicalTrials #UroOncology #Immunotherapy #PatientCare #DrugDevelopment #Immunotherapy #Therapeutics #CGOncology #cretostimogene

Thank you, Urology Times, for sharing the recent news about CG Oncology's Expanded Access Program (EAP) for our novel oncolytic immunotherapy candidate, cretostimogene grenadenorepvec. This program offers a potential pathway of hope for adult patients in the U.S. with Non-Muscle Invasive Bladder Cancer (#NMIBC) who are unresponsive to Bacillus Calmette-Guerin (BCG) and meet certain program eligibility criteria. 📄 Read the article: https://bit.ly/3Ruv3Vq For more information on CG Oncology’s EAP, including eligibility criteria, healthcare providers and bladder cancer patients can visit www.clinicaltrials.gov, NCT06443944, or email EAP@cgoncology.com. #BladderCancer #ClinicalTrials #UroOncology #Immunotherapy #PatientCare #DrugDevelopment #Immunotherapy #Therapeutics #CGOncology #cretostimogene

CG Oncology is thrilled to welcome some key leaders to our organization. These new hires will be critical in our mission of Attacking Bladder Cancer for a Better Tomorrow™! Welcome to CG Oncology: Josh Patterson - General Counsel & Chief Compliance Officer Bob Lapetina - VP, Financial Planning and Analysis  Sarah Connors - Vice President, Communications and Patient Advocacy 

Here at CG Oncology we are thrilled to announce our recent hires who will join us on our quest of Attacking Bladder Cancer for a Better Tomorrow™. Welcome to the team: Allen Kou - Quality Control Manager Anthony R. - Analytical Development Manager Caitlyn Ainge - Director, Technical Accounting and SEC Reporting Scott Tanner - Director, Finance & Accounting Tracy Nazarchyk Pagnozzi - Senior Manager, Medical Writing Jack Lin - Associate Director, CMC Small Molecules

#ICYMI: We recently announced the publication of our Phase 2 CORE-001 final study results of cretostimogene grenadenorepvec in combination with pembrolizumab in Nature Portfolio’s Nature Medicine. Our team is humbled to be part of the innovation and progress related to the treatment of #bladdercancer. A significant highlight at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting was principal investigator Roger Li’s, M.D. poster presentation on the positive CORE-001 data on cretostimogene grenadenorepvec. The study's safety and efficacy findings, now available to the community, demonstrate cretostimogene’s potential as a bladder-sparing backbone therapy for Non-Muscle Invasive Bladder Cancer (#NMIBC). 📄 Read the Nature Medicine article here: https://lnkd.in/guMXCr2t #CORE001 #UroOncology #CancerResearch #ClinicalResearch #PatientCare #ClinicalTrial #Therapeutics #DrugDevelopment #Immunotherapy #CGOncology #cretostimogene #NatureMedicine